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Abstract 
Hyaluronan receptor CD44 mediates interaction between cells and extracellular matrix. The 
expression of standard form and its variants is dysregulated in human leukemias and is associated 
with metastasis and prognosis. The aim of this work is the evaluation of CD44 mRNA and protein 
expression in canine leukemia. Peripheral blood from 20 acute leukemias (AL) (10 acute 
lymphoblastic, 6 acute myeloid and 4 acute undifferentiated leukemias), 21 chronic lymphocytic 
leukemias (CLL) and thirteen healthy dogs were collected. The mRNA expression of all CD44 
variants presenting exons 1–5 and/or 16–20 (CD44_ex1–5 and CD44_ex16–20) and CD44 protein 
were determined by real-time RT-PCR and flow cytometry, using the mean fluorescent index 
(MFI), respectively. CD44 MFI was significantly higher in leukemic samples compared to controls 
and a higher expression was found in AL in respect with CLL. No significant differences were 
found when considering different phenotypic subtypes of AL and CLL. CD44_ex1–5 mRNA 
expression was significantly higher in AL compared to controls, whereas there was no difference in 
CLL compared to controls and AL. CD44_es16–20 showed the same trend, but without differences 
among groups. The high CD44 expression found in canine leukemias could be considered a step 
toward the definition of their molecular features. 
Keywords: CD44; Dogs; Acute leukemia; Chronic lymphocytic leukemia 
 
1. Introduction 
Cell surface hyaluronan receptor CD44 is a transmembrane glycoprotein encoded by a single gene, 
involved in leukocyte recirculation and homing, adhesion to extracellular matrix, angiogenesis, cell 
proliferation and differentiation (DeLisser, 2009). CD44 is encoded by a highly conserved gene of 
approximately 50–60 kb and composed of a number of constant and variable exons: the former 
encoding the extracellular globular domain (exons 1–5), the short stem connecting to the cell 
membrane (exons 16 and 17) and the transmembrane domain (exon 18). The exons 6–15 are 
variable (v1–10), enlarging the stem on its distal site and forming several distinct CD44 isoforms 
(Hertweck et al., 2011). The smallest CD44 molecule lacks the entire variable region and it is 
named CD44 standard (CD44s). CD44s is expressed ubiquitously at high levels in hematopoietic 
cells. Different combinations of the variable exons create a repertoire of several dozen isoforms that 
referred to as CD44 variants (CD44v). However CD44v expression is only restricted to a subset of 
tissues (Liu and Jiang, 2006). 
CD44 has been associated to a number of physiological activities although its expression was 
correlated to tumorigenesis. CD44 was characterized in many tumors mainly stimulating tumor cell 
proliferation and invasiveness by the recruitment and the activation of surface-associated matrix 
metalloproteinaises (Yu and Stamenkovic, 1999). Moreover, CD44 acts as co-receptors for the 
activation of growth promoting tumor receptor tyrosine kinases and specific CD44v functions as 
tumor cell–surface ligands interacting with endothelial selectins to mediate the initial capture and 
arrest of circulating tumor cells at a secondary organ (Hertweck et al., 2011). 
In hematological neoplasms, CD44 is involved in development and progression by enhancement of 
apoptotic resistance, invasiveness, as well as regulation of bone marrow homing, and mobilization 
of leukemia-initiating cells (LIC) into the peripheral blood. In pediatric acute lymphoblastic 
leukemias (ALL), CD44s and CD44v6 have been identified as prognostic markers: high or low 
expression patterns have been reported to differentiate prognostic subgroups in ALL. High CD44v6 
mRNA levels were correlated with increased risk of relapse (Magyarosy et al., 2001). Also, in acute 
myeloid leukemia (AML), CD44 signaling plays a pivotal role based on its involvement in 
differentiation arrest, bone marrow niche dependency of LIC and acquired therapy resistance 
(Hertweck et al., 2011). Some authors reported a remarkable increase in the complexity of CD44v 
expression in cells from patients with AML (Bendall et al., 2004). Its activation in acute 
monoblastic leukemia cells seems to prevent apoptosis (Sansonetti et al., 2012). In neoplasms of 
mature cell, as chronic lymphocytic leukemia (CLL), increased serum levels of soluble CD44 and 
higher expression of CD44 on cell surface are associated with advanced disease, therapy 
requirement and lower median survival (Eisterer et al., 2004). In particular, CD44 displays an anti-
apoptotic effect in CLL cells and a complex of CD44v, CD49d, CD38 and proMMP-9 located on 
the surface of B-CLL cells play a role in migration and in pro-survival signaling, thus promoting the 
accumulation of leukemic cells in the tissues in more advanced and progressive diseases (Buggins 
et al., 2011). 
In dogs, acute leukemias (AL) and CLL show different clinical behavior: while CLL generally has 
an indolent course and a chemotherapeutical approach is required only in cases of progressive 
disease, ALL and AML show an aggressive behavior and a very poor prognosis. However, both 
CLL and AL are poorly characterized in dogs and few pathogenic and prognostic studies are 
available in the literature (Aricò et al., 2013, Comazzi et al., 2011, Giantin et al., 2013 and Usher et 
al., 2009). To the best of our knowledge, no information is present in the veterinary literature on the 
role of CD44 in canine hematopoietic tumors. 
The aim of this work was the evaluation of CD44 mRNA and protein expression in peripheral blood 
from dogs with precursor cell (ALL and AML) and mature cell (CLL) leukemia and to investigate 
possible correlations with different clinical behavior. 
2. Materials and methods 
Peripheral blood (PB) and bone marrow (BM) samples, collected in EDTA tubes, from dogs 
suspected of hematopoietic neoplasm were sent to the Department of Veterinary Sciences and 
Public Health, University of Milan by referring veterinarians for diagnostic purposes. 
Part of the sample was used for routine diagnostic procedures and flow cytometric analysis, while 
the remainder was preserved in polypropylene tubes with 10 parts of RNAlater solution (Life 
Technologies, Foster City, CA) for total RNA isolation. 
PB samples were analyzed with the Sysmex XT-2000iV (Sysmex Corporation, Kobe, Japan). PB 
and BM smears, when available, were stained with May–Grunwald–Giemsa (Merck KGaA, 
Frankfurt, Germany) and used to perform leukocyte differential count and morphological evaluation 
of blast cells. 
Flow cytometric analysis was performed on PB as previously described (Comazzi et al., 2011). The 
following monoclonal antibodies were used: CD45-PE (clone YKIX716.13, Serotec), CD44-FITC 
(clone IM7, Pharmingen), CD3-FITC (clone CA17.2A12, Serotec, T cells), CD4-FITC (clone 
YKIX302.9, Serotec, T-helper and neutrophils), CD8-PE (clone YCATE55.9, Serotec, T-
cytotoxic/suppressor cells), CD5-PE (clone YKIX322.3, T-cell), CD21-PE (clone CA21D6 Serotec, 
mature B cells), CD34-PE (clone 1H6 Pharmingen, precursor cells), CD79a-PE (clone HM57, 
Serotec, B-cells), CD14-PE (clone TUK 4 Serotec, monocytes), CD11b-PEcy5 (clone M1/70 e-
bioscience, myeloid cells), MPO-FITC (clone 2C7,Serotec, myeloid cells). Acquisition was 
performed with FACSCalibur (Becton Dickinson, San Jose, CA) and analysis was conducted by a 
commercially available software (Cell Quest, BD). The following clinical, clinical-pathological and 
immunophenotypical features were used to classify samples: 
-AL: moderate to severe anemia and/or thrombocytopenia, leukocyte morphology suggestive of 
immature or blast cells, more than 20% of blast cells in BM, positivity to CD34, and to CD3, CD5, 
CD4 or CD8 for T-cell acute lymphoblastic leukemia (T-ALL), to CD21, CD79a for B-cell acute 
lymphoblastic leukemia (B-ALL), to at least one myeloid marker for acute myeloid leukemia 
(AML), using the FAB classification (McManus, 2005). Samples were classified as acute 
undifferentiated leukemia (AUL) when atypical cells expressed only CD34 and CD45. 
-CLL: severe lymphocytosis, monomorphic population of mature lymphocytes, positivity to CD3, 
CD5, CD4 or CD8, for T-cell chronic lymphocytic leukemia (T-CLL) and CD21, CD79a for B-cell 
chronic lymphocitic leukemia (B-CLL), negativity to serologic titer for Ehrlichia or Leishmania or 
any other identifiable cause of lymphocytosis. 
Thirteen PB samples from healthy dogs were used as controls. All dogs were privately owned and 
sampled for diagnostic purposes with the informed consent of the owners. A formal approval of the 
Institutional Committee for Animal Care of the University of Milan was not necessary according to 
the internal guidelines since samples were sent for diagnostic purposes. 
Fifty microliters of cells suspension were used for surface staining for CD44-FITC and CD45-PE. 
Cells labeled with the appropriate isotype were used as controls. For each PB sample, the 
mononucleated cells (lymphocytes and neoplastic population) were gated based on morphological 
properties and CD45 staining, by using either the forward scatter (FSC) versus side scatter (SS) dot 
plot then the CD45-PE versus SS dot plot, respectively (Fig. 1). For each sample, the CD44 mean 
fluorescent index (MFI) was calculated as the ratio of MFI of neoplastic cells/MFI of control cells 
(Advani et al., 2008). 
  
Fig. 1.  
Flow cytometric analysis of an acute lymphoblastic leukemia (ALL) sample. Panel A: 
morphological scatter plot with forward scatter (FSC) versus side scatter (SSC). Panel B: scatter 
plot with CD45 versus SSC. Neoplastic cells showed a low SSC and a normal to diminished CD45 
expression. Panel C: scatter plot with CD44 versus CD45. Neoplastic cells were double positive 
with high expression of CD44. 
 
Total RNA was isolated from both cell pellet and RNAlater suspension, using the RNeasy Mini Kit 
(Qiagen, Milan, Italy) according to the manufacturer's instructions. To avoid genomic DNA 
contaminations, on-column DNase digestion with the RNase-free DNase set (Qiagen, Milan, Italy) 
was performed. Total RNA concentration and quality were measured with a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, Germany) and by denaturing gel 
electrophoresis. First-strand cDNA was synthesized as previously described (Giantin et al., 2013). 
The cDNA was used as a template for qPCR analysis. 
In order to detect all possible CD44 variants, primer design was performed considering exons 1–5 
and 16–20, representing CD44 standard exons adjacent to the 5′ and 3′ site of insertion of variants, 
respectively. Primer pairs and the appropriate human Universal Probe Library (UPL) probe were 
selected from canine CD44 mRNA sequence NM_001197022, by using UPL Assay Design Centre 
web service default parameters. Exons 1–5 region (CD44_ex1–5) was amplified with 5′-
AATGCCTTTGATGGACCAAT-3′ (forward primer), 5′-TGTCTTCAGGGTTGGTTCTGT-3′ 
(reverse primer), and number #129 human Universal Probe Library (UPL, Roche Applied Science, 
Indianapolis, IN) probe, while exons 16–20 region (CD44_ex16–20) was amplified with 5′-
GGTCCCATACCACTCATGGA-3′ (forward primer), 5′-GCACCACCTTCTTGACTTCC-3′ 
(reverse primer), and number #130 human UPL probe. Primer specificity was evaluated in silico by 
means of BLAST tool and also experimentally by Power SYBR Green I (Life Technologies, 
Carlsbad, CA) amplification and melting curve analysis. The amplicon size was 94 and 64 base 
pairs for CD44_ex1–5 and CD44_ex16–20, respectively. The qPCR (10 μL final volume) consisted 
of 1× LightCycler 480 Probe Master (Roche Applied Science, Indianapolis, IN), 600 nM forward 
and reverse primers (Eurofins MWG Operon, Ebersberg, Germany), 100 nM human UPL probe and 
2.5 μL of 40-fold diluted cDNA. qPCR analysis was performed in duplicate in a LightCycler 480 
Instrument (Roche Applied Science, Indianapolis, IN) using standard PCR conditions (an activation 
step at 95 °C for 10 min; 45 cycles at 95 °C for 10 s and at 60 °C for 30 s; a cooling step at 40 °C 
for 30 s) and LightCycler 480 clear plates (Roche Applied Science, Indianapolis, IN). No template 
controls and no-reverse transcription controls were included on each plate. Calibration curves, using 
a 2-fold serial dilution of a cDNA pool, revealed a PCR efficiency of 99.0% and 95.5%, an error 
value of 0.066 and 0.086, and a dynamic range of about 7 cycles (22.28–29.64 and 23.52–29.77) for 
CD44_ex1–5 and CD44_ex16–20, respectively. Canine golgin A1 (GOLGA1) was chosen as 
reference gene (Giantin et al., 2013). Data were analyzed with the LightCycler480 software release 
1.5.0 (Roche Applied Science, Indianapolis, IN) by using the fit point method. Messenger RNA 
relative quantification was performed using the ΔΔCt method and a cDNA pool including both 
healthy and pathologic samples as calibrator. 
Statistical analysis was performed with SPSS version 19.0. Kruskal–Wallis test was used to 
compare the gene expression and flow cytometry results for CD44 among healthy dogs and dogs 
affected by AL and CLL and among different phenotypes of acute leukemia (ALL; AML; AUL). 
Statistical significance was set at P < 0.05 for Kruskal–Wallis test and was set at <0.01 for Mann–
Whitney test (post hoc analysis). Grubb's test was used to identify potential outliers. 
3. Results and discussion 
A total of 41 PB samples were analyzed. Based on clinical, hematological and immunophenotypical 
data, in 20 dogs the diagnosis was compatible with AL (10 ALL: 7 B-ALL, 3 T-ALL; 6 AML: 5 
AML4, 1 AML5; 4 AUL), in 21 dogs with CLL (10 T-CLL, 8 B-CLL, 3 with atypical phenotype: 2 
cases of CD3+ CD4− CD8− and 1 case of CD3+ and CD21+). 
The MFI of CD44 in control dogs and in leukemia samples is shown in Table 1. In AL, MFI was 
400.35 ± 167.39 (median value: 429.03) while in CLL was 240.44 ± 131.44 (median value 235.28). 
CD44 MFI was significantly higher in both leukemic groups and in all AL and CLL different 
subtypes when compared to controls (P < 0.001). In addition, a higher expression was found in AL 
compared to CLL (P = 0.001). No statistically significant differences were found between different 
phenotypic subtypes of AL and CLL. However, in CLL a progressive decrease in CD44 expression 
was found in T-CLL compared to B-CLL and atypical CLL. 
Table 1.  
 
CD44 mRNA amount was measured in PB from 6 healthy dogs, 11 AL and 12 CLL. CD44_ex1–5 
mRNA expression was significantly higher in AL compared to controls (P < 0.01), whereas there 
was no difference in CLL compared to controls and AL. CD44_es16–20 mirrored CD44_es1–5 
behavior, but no differences were found among groups (Fig. 2). 
 
 Fig. 2.  
CD44 mRNA expression in peripheral blood of control and leukemic samples. aa: P < 0.001 vs 
control group; CTRL: control dogs; AL: acute leukemia; CLL: chronic lymphocytic leukemia. 
 
In this work, we analyzed the mRNA and protein expression of cell surface hyaluronan receptor 
CD44s in canine leukemias and we found a significantly higher protein expression in AL and CLL 
compared to control dogs and in precursor cell compared to mature cell neoplasms. These data were 
confirmed by the qPCR when comparing AL to control dogs. CD44 plays a pivotal role in the 
development of both myeloid and lymphoid cells mediating the interaction between precursor cells 
and their niches in the bone marrow, favoring lymphocytes migration, reducing Fas-mediated 
apoptosis in T helper cells and playing a proliferation-regulation effect in B lymphocytes (Hertweck 
et al., 2011). As a consequence, altered CD44 expression is crucial in the malignant transformation 
of different hematopoietic tumors in human medicine. High levels of CD44 were correlated with a 
poor outcome in childhood ALL and a higher complexity of CD44v was reported in AML cells 
compared to normal hematopoietic cells (Liu and Jiang, 2006). Interestingly, the block of the 
interaction between CD44 and its ligand by monoclonal antibodies or vaccination is now considered 
a possible therapeutical approach in AL (Hertweck et al., 2011). In veterinary medicine, AL is a 
fatal disease with a very short survival time, due to the massive bone marrow, peripheral blood and 
other organ involvement. In our study, AL showed the highest expression of CD44, both at mRNA 
and protein levels and this could partially explain the aggressive behavior of the disease. The 
presence of an elevated number of CD44 molecules on cell surface could sustain blast cells both in 
the bone marrow and in the peripheral tissue promoting the interaction with the bone marrow 
microenvironment, stimulating the homing and the differentiation arrest of LIC in the hematopoietic 
stem cells niche (Zöller, 2011). Furthermore, CD44 could promote the capture of neoplastic cells on 
endothelial cells strengthening their binding to hyaluronan and, as a consequence, promoting the 
tissue invasion. The similar CD44 expression in different AL subtypes suggests that this mechanism 
is present in blast cells independently of the origin. 
In CLL, we also found a significantly higher CD44 MFI compared to control dogs, even if lower 
than AL. A mechanism of inhibition of apoptosis and increased survival rather than an increased 
proliferation of neoplastic lymphocytes could explain the more indolent course of canine CLL 
compared to AL. A CD44 mediated anti-apoptotic pathway has been demonstrated in human B-
CLL (Fedorchenko et al., 2013), but the association between increased expression and prognosis is 
still undetermined (Fedorchenko et al., 2013 and Herishanu et al., 2011). Our results did not reveal 
any significant difference in CD44 MFI among different phenotypical subtypes which have been 
considered of prognostic value in dog (Comazzi et al., 2011), however a definitive conclusion may 
not be assessed due to the reduced number of cases for each subgroup. mRNA levels of the constant 
region of CD44, composed by exons 1–5, which encodes for the extracellular globular domain, and 
exons 16–20, which encodes for transmembrane region and cytoplasmic tail were also analyzed. 
Both regions showed an over-expression in AL and CLL, but only CD44_ex1–5 were significantly 
higher in AL compared to control dogs. The different results obtained for mRNA and protein 
expression could be related to post-transcriptional control, but this mechanism was not investigated 
in this study. Also, the limited sample number and the high individual variability, particularly in 
exons 16–20 for both AL and CLL samples may alter this association. In a previous work, we 
evaluated the MMP-9 mRNA expression in the same samples used in the current study and we 
found the highest level in CLL (Aricò et al., 2013), but no correlation with CD44 mRNA expression 
was found (data not shown). These molecules, together with CD38 and CD49d, form a 
macromolecular complex in neoplastic B lymphocytes in human B-CLL providing a demonstration 
of the crucial role of the cross-talk between adhesion molecules and pro-angiogenic factors in 
disease progression (Buggins et al., 2011). The lack of correlation between CD44s and MMP-9 in 
our previous results could be evidence for a different scenario in canine CLL, however it's 
important to point out that we analyzed mainly T-CLL and a different interaction between these 
molecules in neoplastic T lymphocytes cannot be excluded. 
Further studies are necessary incorporating a higher number of different AL and CLL subtypes and 
the evaluation of different CD44 variants, both at mRNA and protein level for a better identification 
of the role of the hyaluronan receptor in canine leukemias. In conclusion, this is the first work in 
which CD44 expression was evaluated in canine AL and CLL. In common with the human data, 
also canine AL and CLL display increased CD44 protein expression compared to control samples. 
These results, combined with previous works, where c-KIT expression and a role of angiogenic 
factors, metalloproteinaises and their inhibitors were identified in canine leukemia (Aricò et al., 
2013 and Giantin et al., 2013) represent a step forward in the definition of the molecular features of 
these hematopoietic disorders, identify new target molecules and similarities with human 
leukemias. 
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